K
v
ire
.com
your senior peer reviewer
←
Back
Night
Docs
Editor
Drafts
Library
Search
…
Author
Guillermo Garcia‐Manero
also known as G Garcia-Manero, G García-Manero, G. Garcia-Manero
The University of Texas MD Anderson Cancer Center · Ontario Institute for Cancer Research · Brigham and Women's Hospital · Merck & Co., Inc., Rahway, NJ, USA (United States)
About this author
Works
2,928
Cited by
89,754
h-index
149
i10
1030
ORCID ↗
Top papers
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz, et al.
·
2012
·
Blood
↗ 3,114
OA
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab, et al.
·
2011
·
New England Journal of Medicine
↗ 1,618
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis J. Giles, et al.
·
2003
·
Blood
↗ 816
Acute myeloid leukemia: current progress and future directions
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, et al.
·
2021
·
Blood Cancer Journal
↗ 746
OA
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts, Ryan D. Morin, Jinghui Zhang, et al.
·
2012
·
Cancer Cell
↗ 716
OA
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel‐Wahab, Ann Mullally, Cyrus V. Hedvat, et al.
·
2009
·
Blood
↗ 716
OA
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero, et al.
·
2006
·
Blood
↗ 688
OA
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz, Heinz Tüchler, Françesc Solé, et al.
·
2012
·
Journal of Clinical Oncology
↗ 688
OA
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Hui Yang, Carlos E. Bueso‐Ramos, Courtney DiNardo, et al.
·
2013
·
Leukemia
↗ 678
OA
<i>CCAT2</i>, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
Hui Ling, Riccardo Spizzo, Yaser Atlasi, et al.
·
2013
·
Genome Research
↗ 611
OA
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, et al.
·
2006
·
Cancer
↗ 607
OA
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu, et al.
·
2018
·
Cancer Discovery
↗ 567